Protea Biosciences Group Inc. announced earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported gross revenue totaled $517,569, a 190% increase compared to the third quarter of 2013 and the high revenue for any quarter in the company's history. Net loss was $4,658,776 compared to $2,554,923 for the same period in 2013.

For the nine months, the company reported gross revenue totaled $1,332,230, compared to $938,080 for the same period of 2013, representing a 42% increase. The company's two core lines of business, molecular information services and LAESI instrument platforms, showed greater than 200% increases in gross revenues for the third quarter period over the same period in 2013. Net loss totaled $10,837,252 compared to $7,916,882 for the same period of 2013, which includes a non-cash charge of $2.08 million in fair market value on derivatives related to anti-dilution protection on certain securities.